Skip to main content

CBE Nexus · Bachelor of Science in Biotechnology

Chapter 8: Animal Biotechnology and Medical Biotechnology

Animal cell systems, reproductive technologies, vaccines, biologics, diagnostics, regenerative medicine, gene and cell therapy, ethics and regulation.

Course catalogue

Home › University Biology › Biotechnology › Chapter 8

Learning outcomes

By the end of this chapter, learners should be able to define and explain its principal concepts, connect biological mechanisms to practical applications, evaluate evidence, identify limitations and discuss safety, ethical and societal considerations. Use your institution's module outline to confirm local learning outcomes and prescribed depth.

Academic and safety note: These notes support independent study. They are not a substitute for approved laboratory manuals, supervision, institutional biosafety procedures, clinical advice or current national regulation. Do not perform biological procedures without appropriate training, authorisation and facilities.

1. Scope and foundational concepts

Animal biotechnology applies biological methods to animal health, reproduction, production, conservation and biomedical research. Medical biotechnology uses cells, genes, proteins and biological systems to prevent, diagnose or treat disease. These areas overlap in vaccine development, biologics manufacturing, disease models and comparative medicine, but their intended uses and regulatory pathways may differ substantially.

A central principle is that biological products are complex. Their behaviour depends on cell type, culture conditions, genetic stability, processing, formulation and storage. Claims of efficacy or safety require evidence appropriate to the intended use. Preclinical findings can support further investigation but do not by themselves establish that an intervention is safe or effective in people.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

2. Animal cell culture and biomanufacturing

Animal cell culture provides a controlled environment for studying cell behaviour and producing complex biological molecules. Mammalian cells are widely used where protein folding and post-translational modifications are important. Cell substrates require authentication, contamination control, genetic stability assessment and traceable banking. A culture system must be characterised over the period and scale relevant to production.

Biomanufacturing links upstream cell growth and product expression with downstream recovery, purification, formulation and quality testing. Critical quality attributes may include identity, purity, potency, aggregation, glycosylation and residual process-related materials. Process changes can affect product comparability, so manufacturing science and quality systems are integral to biotechnology.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

3. Reproductive and developmental biotechnology

Animal reproductive technologies include artificial insemination, embryo transfer, in vitro fertilisation and cryopreservation of gametes or embryos. These methods can support breeding programmes, conservation and research. Their use raises questions about animal welfare, genetic diversity, disease transmission, ownership and equitable access.

Outcomes depend on species, genetics, reproductive physiology, health, management and technical expertise. Increasing reproductive efficiency should not be pursued without monitoring welfare and long-term population effects. Conservation programmes must avoid narrowing genetic diversity or treating reproductive technologies as substitutes for habitat and ecosystem protection.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

4. Vaccines and immunobiotechnology

Vaccines expose the immune system to an antigen or antigen-encoding platform in a way intended to generate protective immune memory. Platforms include live attenuated, inactivated, subunit, conjugate, viral-vector and nucleic-acid approaches. Platform selection depends on pathogen biology, target population, immune response, manufacturing capacity, stability and safety considerations.

Vaccine development progresses through antigen research, preclinical evaluation, clinical studies, manufacturing validation and regulatory review. Immunogenicity is not always equivalent to clinical protection. Effectiveness can vary with age, immune status, pathogen evolution and delivery conditions. Surveillance after deployment helps identify rare adverse events and changes in pathogen epidemiology.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

5. Therapeutic proteins and monoclonal antibodies

Biological medicines include hormones, enzymes, cytokines, clotting factors and monoclonal antibodies. Their molecular size and structural complexity distinguish them from many small-molecule drugs. A biologic's activity may depend on conformation, disulphide bonds, glycosylation and other modifications, making analytical characterisation and controlled manufacturing essential.

Biosimilars are highly similar biological products evaluated against a reference product using a totality-of-evidence approach. They are not simply generic copies in the same sense as many small-molecule medicines. Comparative analytical, functional and clinical evidence supports regulatory decisions, while pharmacovigilance monitors safety and effectiveness in real-world use.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

6. Gene therapy and cell therapy

Gene therapy seeks to treat or prevent disease by introducing, removing or changing genetic material in cells. Cell therapies use living cells as therapeutic agents, sometimes after modification or expansion. Approaches may be ex vivo, where cells are modified outside the body, or in vivo, where delivery occurs within the patient. The choice affects manufacturing, delivery, monitoring and risk.

Potential risks include immune responses, off-target effects, insertional changes, cell migration, persistence and manufacturing variability. Long-term follow-up may be required depending on the product. Ethical assessment should consider consent, uncertainty, cost, access, vulnerable populations and the distinction between somatic interventions and heritable germline changes.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

7. Diagnostics and precision medicine

Medical biotechnology supports diagnostics through immunoassays, molecular tests, sequencing, biomarkers and companion diagnostics. A test must be evaluated for analytical validity, clinical validity and clinical utility. Sensitivity and specificity describe performance under defined conditions, but predictive values also depend on disease prevalence and the population being tested.

Precision medicine uses biological and clinical information to guide prevention or treatment. Genomic information may reveal incidental findings or information relevant to relatives, creating privacy and consent challenges. Algorithms and biomarkers can perform differently across populations if reference datasets are unrepresentative. Equity requires validation across diverse groups and access to appropriate follow-up care.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

8. Animal models and alternatives

Animal models have contributed to understanding physiology and disease, but species differences limit translation. Model selection should be justified by the research question, and study design should minimise bias through randomisation, blinding, appropriate sample size and transparent reporting. The principles of replacement, reduction and refinement guide ethical use of animals in research.

Alternatives include cell systems, organoids, organ-on-chip models, computational methods and human tissue-based approaches. These methods can improve human relevance for some questions but may not reproduce whole-organism interactions. A scientifically sound programme selects the most appropriate model and combines evidence where necessary rather than assuming that one model answers every question.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

9. Regulation, quality and pharmacovigilance

Medical biotechnology is governed by quality, safety and efficacy requirements that vary by jurisdiction and product class. Good manufacturing practice, validated analytical methods, controlled documentation and traceability support consistent production. Clinical trials require ethical review, informed consent, participant protection and independent oversight.

After approval, pharmacovigilance and product-quality monitoring continue. Adverse-event reports, batch investigations and real-world evidence can reveal issues not detected in trials. Regulatory compliance is not a one-time administrative step; it is a lifecycle responsibility shared by developers, manufacturers, healthcare professionals and authorities.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

10. Ethics, access and societal implications

Medical and animal biotechnology raise questions about affordability, access, animal welfare, genetic privacy, ownership of biological materials and fair distribution of benefits. High-cost therapies may widen inequalities if financing and health-system capacity are not considered. Research involving animals or human participants requires appropriate review, consent and safeguards.

Public trust depends on honest communication about evidence, uncertainty, risks and alternatives. Community engagement should begin early enough to influence research priorities and design. Responsible innovation asks not only whether a technology can be developed, but whether it addresses a meaningful need, who can access it and what monitoring is needed.

Critical study point: Explain the biological principle in your own words, identify the evidence needed to support a conclusion, and state at least one limitation or source of uncertainty. Connect the concept to an authentic application without assuming that laboratory feasibility guarantees real-world benefit.

Conceptual workflow
Define problem→Choose biological system→Design and test→Validate evidence→Evaluate impact
Evidence and quality cycle
Sample / material→Measurement→Quality control→Analysis→Independent confirmation
Responsible innovation framework
Scientific merit+Safety+Ethics+Equity+Monitoring

Applied case study

A research or production team is considering a biotechnology intervention to address a defined challenge. Before implementation, the team must establish the baseline problem, identify the biological mechanism, compare alternative approaches and define measurable success criteria. It should assess technical feasibility, resource requirements, quality controls, potential hazards and the distribution of benefits and risks.

The team develops a study plan with appropriate controls and independent measurements. Results are analysed against predefined endpoints, including uncertainty and unexpected observations. The team then considers whether evidence supports further development, whether additional validation is required or whether the approach should be revised or discontinued. This decision-based approach prevents attractive preliminary findings from being mistaken for proof of practical effectiveness.

Practical learning activity: design an evidence plan

  1. Write a focused research question relevant to this chapter.
  2. State a testable hypothesis and identify the independent and dependent variables.
  3. Identify positive, negative and process controls where appropriate.
  4. Specify the sample type, measurement method and quality checks.
  5. Explain how results would be analysed and independently validated.
  6. Identify biosafety, ethics, environmental and data-governance requirements.
  7. Present a short report distinguishing observations, interpretation and limitations.

Assessment rubric: Scientific accuracy (25%); study design and controls (25%); interpretation and limitations (20%); safety and ethics (15%); clarity, referencing and reproducibility (15%).

Revision and examination questions

  1. 1. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  2. 2. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  3. 3. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  4. 4. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  5. 5. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  6. 6. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  7. 7. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  8. 8. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  9. 9. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  10. 10. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  11. 11. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  12. 12. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  13. 13. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  14. 14. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

  15. 15. Explain a central principle from this chapter and show how it informs a biotechnology application. In your answer, define key terms, describe the evidence required and discuss one limitation.

    Marking guidance: Award credit for accurate terminology, a logical explanation, relevant application, appropriate evidence and critical evaluation.

Revision checklist

Further study: Consult current undergraduate biotechnology textbooks, peer-reviewed reviews, primary research and guidance from relevant scientific and regulatory bodies. Verify that sources are current and applicable to your jurisdiction.

← Return to Biotechnology course catalogue

Official Education References

Use these official organisations for curriculum guidance, examinations and further learning information.